Sun, Jan 25, 2015, 9:50 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Array BioPharma, Inc. Message Board

  • dcaf7 dcaf7 Apr 24, 2013 7:21 PM Flag

    Selumetinib abstract titles at ASCO 2013


    Abstract #CRA9003
    2:15 PM - 2:30 PM
    Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).
    Richard D. Carvajal, MD

    Abstract #9004
    2:30 PM - 2:45 PM
    Phase II double-blind, randomized study of selumetinib (SEL) plus dacarbazine (DTIC) versus placebo (PBO) plus DTIC as first-line treatment for advanced BRAF-mutant cutaneous or unknown primary melanoma.
    Mark R. Middleton, PhD, FRCP


    Abstract #9068
    DOC-MEK: A double-blind randomized phase II trial of docetaxel with or without selumetinib (AZD6244; ARRY-142886) in wt BRAF advanced melanoma.
    Avinash Gupta, MBBS BSc MRCP

    Abstract #TPS4145
    SWOG S1115: Randomized phase II clinical trial of selumetinib (AZD6244; ARRY 142886) hydrogen sulfate (NSC-748727) and MK-2206 (NSC-749607) versus mFOLFOX in patients withmetastatic pancreatic cancer after prior chemotherapy.
    Vincent M. Chung, MD

    Abstract #3587
    The MEK inhibitor selumetinib ([SEL], AZD6244, ARRY-142886) plus irinotecan (IRI) as second-line therapy for KRAS-mutated (KRASm) metastatic colorectal cancer (CRC).
    Howard S. Hochster, MD

    Abstract #8026
    Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations.
    Corey A. Carter, MD
    Poster Board: #15

    Abstract #4014
    Dual MEK/EGFR inhibition for advanced, chemotherapy-refractory pancreatic cancer: A multicenter phase II trial of selumetinib (AZD6244; ARRY-142886) plus erlotinib.
    Andrew H. Ko, MD
    Poster Board: #6

    SortNewest  |  Oldest  |  Most Replied Expand all replies
7.11+2.060(+40.79%)Jan 23 4:00 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.